3.63
-0.09 (-2.42%)
-0.09 (-2.42%)
Upgrade to Real-Time
Afterhours (Closed)
| Volume | 6,711 |
|
|||||
| News | - | ||||||
| Day High | 3.8711 | Low High |
|||||
| Day Low | 3.72 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Aeterna Zentaris Inc | AEZS | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.09 | -2.42% | 3.63 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 3.74 | 3.72 | 3.8711 | 3.82 | 3.72 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 82 | 6,711 | $ 3.84 | $ 25,752 | - | 0.1645 - 5.90 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 17:14:45 | formt | 100 | $ 3.63 | USD |
Period:
Draw Mode:
Aeterna Zentaris Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 17.63M | 4.86M | 4.85M | $ 5.26M | $ - | -1.87 | -1.50 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | - | - |
Aeterna Zentaris News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AEZS Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 3.66 | 3.94 | 3.66 | 3.78 | 11,766 | -0.03 | -0.82% |
| 1 Month | 3.38 | 3.94 | 3.37 | 3.76 | 13,279 | 0.25 | 7.4% |
| 3 Months | 3.68 | 4.00 | 2.89 | 3.57 | 15,776 | -0.05 | -1.36% |
| 6 Months | 4.63 | 5.90 | 2.89 | 4.51 | 30,626 | -1.00 | -21.6% |
| 1 Year | 0.35 | 5.90 | 0.1645 | 0.4433629 | 431,941 | 3.28 | 937.14% |
| 3 Years | 1.03 | 5.90 | 0.1645 | 1.13 | 3,029,263 | 2.60 | 252.43% |
| 5 Years | 2.05 | 5.90 | 0.1645 | 1.20 | 1,920,684 | 1.58 | 77.07% |
Aeterna Zentaris Description
| AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland. |
